Axogen director gains 14,150 shares via RSU vesting

Axogen, Inc. director Alan M. Levine reported the vesting of restricted stock units and corresponding acquisition of common shares as part of his annual board compensation.

Rhea-AI Filing Summary

Axogen, Inc. director Alan M. Levine reported the vesting of restricted stock units and corresponding acquisition of common shares as part of his annual board compensation. On June 19, 2026, 14,150 restricted stock units vested, converting into 14,150 shares of Axogen common stock at no cash exercise price.

Each unit represented the right to receive one share, based on an equity grant valued at $150,000 as of the grant date. After this vesting and conversion, Levine directly holds 50,893 shares of Axogen common stock, reflecting a compensation-related, non‑market transaction rather than an open‑market purchase or sale.

Insider Trade Summary

14,150 shares exercised/converted

Exercise 2 txns

Insider Levine Alan M

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	14,150	$0.00	$0.00
Exercise	Common Stock	14,150	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 0 contracts (Direct); Common Stock — 50,893 shares (Direct)

Footnotes (3)

1. F1. This reflects the number of restricted stock units that vested June 19, 2026.
2. F2. Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
3. F3. Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

Key Figures

RSUs vested: 14,150 units Shares acquired from RSUs: 14,150 shares Director share holdings after transaction: 50,893 shares +2 more

5 metrics

RSUs vested 14,150 units Restricted stock units vested on June 19, 2026

Shares acquired from RSUs 14,150 shares Common stock received upon RSU vesting

Director share holdings after transaction 50,893 shares Direct ownership after June 19, 2026 transaction

Equity grant valuation $150,000 Value of annual director equity grant at grant date

RSU exercise price $0.0000 per unit Conversion price for restricted stock units into common shares

Key Terms

Restricted Stock Units, derivative security, annual equity grant, contingent right

4 terms

Restricted Stock Units financial

"This reflects the number of restricted stock units that vested June 19, 2026."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

annual equity grant financial

"Annual equity grant for service as Director on the Axogen, Inc. Board of Directors."

contingent right financial

"Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Axogen (AXGN) director Alan M. Levine report in this Form 4?

Alan M. Levine reported the vesting of 14,150 restricted stock units, which converted into 14,150 shares of Axogen common stock. This reflects compensation for his service as a director, not an open-market stock purchase or sale.

How many Axogen (AXGN) shares does Alan M. Levine own after this transaction?

Following the RSU vesting and conversion, Alan M. Levine directly holds 50,893 shares of Axogen common stock. This total reflects his updated direct ownership position after receiving 14,150 shares from vested restricted stock units.

Was cash involved in Alan M. Levine’s Axogen (AXGN) Form 4 transaction?

No cash changed hands in this transaction. The 14,150 restricted stock units vested at a stated price of $0.0000 per unit, automatically converting into 14,150 shares of Axogen common stock as part of his equity compensation.

What is the origin of the 14,150 RSUs reported by Axogen (AXGN) director Levine?

The 14,150 restricted stock units came from an annual equity grant for Alan M. Levine’s service on Axogen’s board. The grant was based on a $150,000 valuation at the grant date and vested on June 19, 2026, one year after the grant.

Do the vested RSUs in this Axogen (AXGN) Form 4 represent an open-market stock purchase?

The vested RSUs do not represent an open-market purchase. They reflect compensation awarded as restricted stock units that automatically converted into common shares upon vesting, rather than shares bought or sold in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2026 - 04:37 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Levine Alan M

(Last) (First) (Middle)

C/O AXOGEN, INC. 13631 PROGRESS BLVD.

SUITE 400

(Street)

ALACHUA FLORIDA 32615

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Axogen, Inc. [ AXGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/19/2026		M		14,150(1)	A	$0	50,893	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	06/19/2026		M		14,150		(3)	(3)	Common Stock	14,150	$0	0	D

Explanation of Responses:

1. This reflects the number of restricted stock units that vested June 19, 2026.

2. Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

3. Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $150,000 valuation as of the grant date and vests on June 19, 2026, the one-year anniversary of the grant date.

Remarks:

	/s/ Marc Began, as attorney-in-fact for Alan Levine	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)